Connect with us

Business

Take a Pill to Quit Smoking Weed? – Cannabis Use Disorder Pill Starts Clinical Trials

Published

on

What is Cannabis Use Disorder and do you need a pill to help you get off weed?

pill to quit weed

While many cannabis producers and marketers might not want to openly declare it, excessive use of cannabis is detrimental to health. Cannabis Use Disorder has been the name used to describe this condition and has seen been as a matter for the pharmaceutical industry to give an answer to. It would seem that Segal Trials has done just that as its new drug is set to commence clinical trials for cannabis use disorder.  Read on as we explore all that there is to know about the new drug that is set to begin its clinical trials.

Cannabis Use Disorder

Cannabis Use Disorder is a condition where severe use of cannabis leads to dependency in the user and promotes deleterious effects. Common symptoms of cannabis use disorder include depression, restlessness, anxiety, irritability, anxiety, and dysphoria. It is also known as cannabis addiction or marijuana addiction. The point of tagging a condition as cannabis use disorder is when the user doesn’t cease its use despite apparent social and health problems being linked to its use.

The prolonged use of cannabis which causes the user to develop tolerance to the effects of THC is one of the mechanisms causing cannabis use disorder. This causes dependency in some chronic cannabis users and any attempt to cease causes withdrawal symptoms. Another factor that can promote the early onset of this condition in some individuals is the drastic increase in the potency of cannabis taken. A change in the mode of delivery can also hasten the development of dependency and eventually cannabis use disorder.

Is a pharmaceutical solution on the way?

The issues associated with a dependency that comes with cannabis use disorder are there for all to see but a pharmaceutical solution is already on the horizon. Segal Trials, a clinical research network based in South Florida recently announced that it will soon commence Phase 2B study for a new drug for cannabis use disorder. The drug designated as AEF0117-202 as disclosed in a press release on October 5 is being created by Aelis Farma. The Phase 2 study that is about to commence is a random, double-blind, placebo-controlled study. The study will consist of 4-arms, a parallel group and a multicenter towards determining its efficacy.

The new drug is being classified under a new class of drugs called sCB1-SSi. It will be the first of such drugs chosen as a clinical candidate towards the treatment of cannabis use disorder. The drug is expected to react to the same endocannabinoid receptors as THC in the body. This effect is expected to create a stop in the dependency and halt the progression of deleterious symptoms that might come with withdrawal.

More on the clinical trials

For the purpose of the trials to be carried out to determine the efficacy of the drug, a criterion has been set to classify how much cannabis is too much. People with cannabis use disorder are defined as those who use cannabis five times per week or more. Such selected individuals are to be chosen as study participants. A group of these participants are to be administered the trial drug orally while another group will be given a placebo.

Three different doses of the trial drug (0.1mg, 0.3mg, and 1.0mg) are to be given to the study participants in capsules. Results from the test will justify the hypothesis that since AEF0117 acts across similar receptors as THC, it can alter some of the effects of cannabis. The Medical Director and Chief Scientific Officer at Segal Trials, Rishi Kakar believes the study will help people desperate to end their reliance on cannabis.

The cannabis withdrawal symptoms being used in the study include cravings, restlessness, decreased appetite, irritability, and mood and sleep difficulties. A recent study by the Center for Disease Control and Prevention shows that 3 of 10 cannabis users suffer from cannabis use disorder. Another study also shows that there is a 10 percent chance that people who use cannabis will become addicted. This shows the importance of the work being done by Segal Trials on the development of a pharmaceutical drug for cannabis use disorder.

The trial for the new drug to be done by Segal Trials is said to be done at the Center for Psychedelic and Cannabis Research. The centre was specifically built for such structured trials to promote patient comfort and patient safety while conducting the trials. The team has also worked on psychedelics to conduct a clinical trial on the efficacy of LSD D-tartrate for treating general anxiety disorder. This serves as a foundational basis for which the group seeks to establish this new drug as a solution to cannabis use disorder.

Factors promoting the rise in cannabis use disorder

One of the major factors that have been identified for the increase in cannabis use disorder is the rise in dabbing. The presence of new and modified modes of delivery of cannabis has resulted in an increase in the potency of THC as more concentrates are being developed. This has resulted in the development of cannabis products with high potency over the last twenty years.

The absence of an approved drug for cannabis use disorder has also increased the incidence of the condition. The lack of a proper definition of the condition for a long time resulted in a lack of clinical research on it for quite some time. This in turn created an absence of considerable literature that is needed to facilitate the development of the pharmaceutical drug.

Summary

The development of the new drug and the commencement of its clinical trials are definitely comforting news for many. The menace of cannabis use disorder is one that many have continued to shy away from for quite some time. However, if the results of these clinical trials come back successful then we can be looking towards the development of a new era. An era where cannabis dependency and withdrawal symptoms are a thing that can be corrected by the work of a pharmaceutical pill.

Source: https://cannabis.net/blog/medical/take-a-pill-to-quit-smoking-weed-cannabis-use-disorder-pill-starts-clinical-trials

Business

Alleged Crores Pharma Scam Mastermind Arrested from Surat

Published

on

By

After evading law enforcement for nearly 13 years, an accused linked to a large-scale pharmaceutical fraud case has been arrested by Delhi Police from Surat, Gujarat. The suspect is alleged to have orchestrated a series of financial scams involving fake identities, forged documents, and dishonoured cheques used to procure high-value pharmaceutical raw materials.

Authorities say the accused, identified as Himmat Singh Lodha, is believed to have defrauded multiple pharmaceutical companies in Delhi of goods worth approximately ₹98 lakh before disappearing and remaining underground for years.

Fake Business Deals and Dishonoured Cheques Used in Fraud

Investigators claim the accused posed as a legitimate pharmaceutical trader and placed bulk orders for expensive drug ingredients, offering post-dated cheques as payment security.

In one documented case from 2013, he allegedly obtained around 550 kilograms of Gliclazide, a diabetes-related pharmaceutical ingredient, valued at over ₹26 lakh. When suppliers attempted to encash the cheques, they were reportedly returned with the remark “account closed.”

Following the transaction, the accused allegedly vacated his office and rented residence and disappeared without settling payments. He was later declared a proclaimed offender in 2016 after repeatedly failing to appear before court proceedings. Authorities had also issued a reward for information leading to his arrest.

Multiple Identities and Repeated Fraud Pattern

Police investigations further link the accused to another cheating case dating back to 2012, where he allegedly used a fake identity, “Kailash Jain,” to obtain a large consignment of Ambroxol HCL, a pharmaceutical compound used in cough medications. The value of that consignment was estimated at around ₹72 lakh.

Officials believe the accused followed a consistent modus operandi—posing as a credible businessman, securing high-value goods on deferred payment terms, and then disappearing after delivery while shutting down business operations.

Investigators suspect that forged business records, fake company credentials, and fabricated financial histories were used to build trust with suppliers and gain access to expensive raw materials.

Multi-State Surveillance Leads to Arrest in Surat

A special Crime Branch team tracked the accused through coordinated surveillance efforts across multiple cities, including Mumbai, Ahmedabad, and Surat. After nearly a month of technical monitoring and intelligence gathering, officials located and arrested him from a residential area in Surat.

Authorities also revealed that the accused had been involved in property-related activities while staying under the radar to avoid detection.

Growing Threat of Corporate Identity Fraud

The case highlights a rising trend of organised financial fraud targeting industries that rely heavily on trust-based transactions and deferred payments. Experts note that criminals increasingly exploit gaps in corporate verification systems by using fake GST registrations, temporary offices, and forged documentation to appear legitimate.

Cybercrime and financial fraud specialists warn that such schemes are becoming more complex with the widespread availability of digital business tools, making it easier to create convincing but fraudulent corporate identities.

Experts Urge Stronger Due Diligence in High-Value Transactions

Experts, including former IPS officer and cybercrime specialist Prof. Triveni Singh, emphasize the need for stricter verification procedures in commercial dealings. He noted that relying solely on paperwork or digital business profiles can expose companies to significant financial risk.

Authorities and industry experts recommend physical verification of business operations, bank account validation, and detailed background checks before engaging in high-value or deferred-payment transactions—particularly in sectors like pharmaceuticals, where single consignments can involve transactions worth crores.

Continue Reading

Business

EU Pressure Builds on Google as Regulators Face Calls for Massive Fine Over Search Practices

Published

on

By

A growing coalition of European industry groups is intensifying pressure on regulators to take decisive action against Google over allegations of unfair search practices that could reshape competition rules across the region’s digital economy.

Investigation Under Digital Markets Act Gains Momentum

The case is being examined by the European Commission under the European Union’s landmark Digital Markets Act (DMA), introduced to curb the dominance of major technology platforms and ensure fair competition.

Launched in March 2024, the investigation focuses on whether Google has been prioritising its own services in search results, potentially disadvantaging rival businesses that rely on online visibility to reach customers.

Industry Groups Demand Swift Action

Several prominent European organizations have jointly urged regulators to conclude the probe without further delay. They argue that prolonged investigations allow alleged anti-competitive practices to continue, putting European companies—especially startups—at a disadvantage.

Signatories include the European Publishers Council, the European Magazine Media Association, the European Tech Alliance, and EU Travel Tech.

In a joint statement, these groups warned that delays in enforcement are affecting innovation, profitability, and growth prospects for regional businesses competing in digital markets.

Google Denies Allegations

Google has rejected claims of bias, stating that its search algorithms are designed to deliver the most relevant and useful results to users. The company has also proposed adjustments to address regulatory concerns.

However, critics argue that these changes are insufficient and fail to address the core issue of market dominance.

Potential Billion-Euro Penalties

If found in violation of the DMA, Google could face significant financial penalties. Under EU rules, fines can reach a substantial percentage of a company’s global turnover, potentially amounting to billions of euros.

Regulators may also impose corrective measures requiring changes to business practices, which could have long-term implications for how digital platforms operate in Europe.

Wider Implications for Big Tech

The case highlights ongoing tensions between European regulators and major U.S. technology firms. In recent years, the EU has taken a more aggressive stance in enforcing competition laws, aiming to create a level playing field for local businesses.

A final ruling against Google could set a major precedent, influencing future enforcement actions and shaping the regulatory landscape for global tech companies operating within Europe.

As scrutiny intensifies, the outcome of the investigation is expected to play a critical role in defining the future of digital competition across the European Union.

Continue Reading

AI & Technology

Amazon Faces Potential Criminal Trial in Italy Over €1.2 Billion Tax Evasion Allegations

Published

on

By

Milan: U.S. tech giant Amazon is facing the prospect of a major legal showdown in Italy, after prosecutors in Milan formally requested a court to move forward with criminal proceedings over alleged tax evasion totaling approximately ₹12,500 crore (€1.2 billion).

The case targets Amazon’s European division along with four senior executives, marking one of the most significant tax-related investigations involving a global e-commerce platform in Europe.

Trial Push Despite Multi-Million Euro Settlement

The move comes even after Amazon reached a financial settlement with Italian tax authorities in December, agreeing to pay around ₹5,500 crore (€527 million), including interest, to resolve part of the dispute.

Typically, such settlements lead to the closure of criminal investigations. However, Milan prosecutors have opted to proceed, signaling a tougher stance on alleged corporate tax violations.

A preliminary hearing is expected in the coming months, where a judge will decide whether to formally indict the company and its executives or dismiss the case.

Allegations of VAT Evasion Through Marketplace Sellers

At the center of the investigation are claims that Amazon’s platform enabled non-European Union sellers to avoid paying value-added tax (VAT) on goods sold to Italian consumers between 2019 and 2021.

Prosecutors allege that the company’s marketplace structure allowed thousands of foreign vendors—many reportedly based in China—to operate without fully disclosing their identities or tax obligations. This, authorities argue, led to substantial VAT losses for the Italian government.

Under Italian law, online platforms facilitating sales can be held partially liable if third-party sellers fail to comply with tax requirements, a key point in the prosecution’s case.

Italian Government Named as Affected Party

In their filing, prosecutors identified Italy’s Economy Ministry as the injured party, citing significant financial damage resulting from the alleged tax evasion.

Legal experts say the outcome of the case could have wide-ranging implications across the European Union, where VAT systems are harmonized and similar compliance rules apply to digital marketplaces.

Multiple Investigations Add to Pressure

The VAT probe is just one of several legal challenges facing Amazon in Italy. The European Public Prosecutor’s Office is reportedly examining additional tax-related issues covering more recent years.

Meanwhile, Milan authorities are pursuing separate investigations into alleged customs fraud linked to imports from China and whether Amazon maintained an undeclared “permanent establishment” in Italy—potentially exposing it to higher tax liabilities.

In a separate regulatory action, Italy’s data protection authority recently ordered an Amazon unit to stop using personal data from over 1,800 employees at a warehouse near Rome.

Amazon Denies Allegations

Amazon has consistently denied wrongdoing and indicated it will strongly contest the allegations in court if the case proceeds. The company has also warned that prolonged legal uncertainty could impact investor confidence and Italy’s appeal as a destination for international business.

Broader Impact on Europe’s Digital Economy

If the case moves to trial, it could become a landmark moment for the regulation of global e-commerce platforms in Europe. Governments across the region are increasingly scrutinizing how digital marketplaces handle tax compliance, especially in cross-border transactions.

With online retail continuing to expand, regulators are under mounting pressure to ensure that multinational platforms and third-party sellers adhere to the same tax rules as traditional businesses.

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News